BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Reistone Biopharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Reistone Biopharma's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04957550-29@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:ivarmacitinib: Phase 3 readout est. (NCT04957550)
DESCRIPTION:ivarmacitinib\, phase 3.\nStudy: To Evaluate the Efficacy and S
 afety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis\nEstimat
 ed primary completion: 13 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04957550
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543224-1475@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:RSS0393: Phase 3 readout est. (NCT07543224)
DESCRIPTION:RSS0393\, phase 3\, Psoriasis.\nStudy: A Multicenter\, Randomiz
 ed\, Double-Blind\, Placebo-Controlled Phase III Clinical Study to Evaluat
 e the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaqu
 e Psoriasis.\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rss0393#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07543224
URL:https://assetmemo.bio/drug/rss0393#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07251595-29@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT07251595)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: A Trial of SHR0302 Tablets and
  SHR0302 Base Gel in Patients With Non-segmental Vitiligo\nEstimated prima
 ry completion: March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ivarmacitinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07251595
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349524-1551@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:RSS0343: Phase 2 readout est. (NCT07349524)
DESCRIPTION:RSS0343\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Pati
 ents With Chronic Obstructive Pulmonary Disease\nEstimated primary complet
 ion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rss0
 343#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07349524
URL:https://assetmemo.bio/drug/rss0343#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
